Patient perspectives of prosthetic heart valve choice and anticoagulation in patients with rheumatic heart disease: a semi-quantitative study - Scorecard - MDSpire

Patient perspectives of prosthetic heart valve choice and anticoagulation in patients with rheumatic heart disease: a semi-quantitative study

  • By

  • Shownok Saha

  • Danielle Gelbart

  • Francesco Pirone

  • David J. McCormack

  • Nishith N. Patel

  • June 8, 2026

  • 0 min

Share

Clinical Scorecard: Exploring Patient Insights on Prosthetic Heart Valve Selection and Anticoagulant Management in Individuals with Rheumatic Heart Disease: A Semi-Quantitative Analysis

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients aged 18-60 years with RHD who underwent valve replacement surgery.
Care Setting

Key Highlights

  • follow_up

Guideline-Based Recommendations

Diagnosis

    Management

    • Prioritize durable valve repair over prosthetic replacement where feasible.
    • Consider specific anticoagulation strategies based on valve type.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Include implications of patient preferences for anticoagulation management.

        Clinical Best Practices

        • best_practices

        Related Resources & Content

        Original Source(s)

        Patient perspectives of prosthetic heart valve choice and anticoagulation in patients with rheumatic heart disease: a semi-quantitative study

        • by Shownok Saha, Danielle Gelbart, Francesco Pirone, David J. McCormack, Nishith N. Patel

        • June 8, 2026

        Related Content

        Cardiovascular protection by SGLT2 inhibitors: an integrative review of mechanistic networks, clinical evidence, and safety considerations

        Can Finerenone Alter Glomerular Disease Trajectory?

        A prespecified exploratory analysis of the FIND-CKD clinical trial examined kidney function, albuminuria, and kidney failure outcomes in 903 patients with glomerular diseases.

        Oral HRS-7535 Lowered A1c in Trial

        Nonpeptide oral agent requires no fasting administration.